John Oliver and a delightful melange of celebrities explain the benefits and pitfalls of compounding pharmacies
"When you picture a pharmacy in your mind, you probably imagine a place that your doctor calls in a prescription and someone counts out pills that were manufactured somewhere else, but that is actually a fairly new phenomenon," John Oliver said on Sunday's Last Week Tonight. "A lot of pharmacies used to make medications on-site," and "there are still places that still make their drugs from scratch." America's roughly 7,500 compounding pharmacies "exist for a very good reason," he explained: To make "bespoke medications" for people (and animals) with special needs.
"But as you've probably guessed by the very fact we're talking about this story in the first place, there are some huge problems" with compounding pharmacies, Oliver said. "As you will see, oversight is so lax that compounding pharmacies have become the Wild West of the drug industry, resulting in fraud and, in the worst cases, many, many people dying. And you may not even know that you're taking a compounded drug."
Oliver started with fraud, then moved on to deaths, and some of the stories are pretty harrowing, including a still-operational compounding pharmacy in Texas that made its eye injection formula with formaldehyde and acetone, blinding about 70 people. "It's frankly not unreasonable to want a world where you can feel confident that something that's about to be injected into your eyeball is at least as safe as lettuce," he said. There is NSFW language throughout, but the delightfully eccentric ending, featuring a bunch of random celebrities mentioned earlier in the segment, is definitely something you shouldn't watch at work without headphones on. Peter Weber
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Peter has worked as a news and culture writer and editor at The Week since the site's launch in 2008. He covers politics, world affairs, religion and cultural currents. His journalism career began as a copy editor at a financial newswire and has included editorial positions at The New York Times Magazine, Facts on File, and Oregon State University.
-
Honda and Nissan in merger talks
Speed Read The companies are currently Japan's second and third-biggest automakers, respectively
By Peter Weber, The Week US Published
-
Taylor Swift wraps up record-shattering Eras tour
Speed Read The pop star finally ended her long-running tour in Vancouver, Canada
By Peter Weber, The Week US Published
-
Drake claims illegal boosting, defamation
Speed Read The rapper accused Universal Music of boosting Kendrick Lamar's diss track and said UMG allowed him to be falsely accused of pedophilia
By Rafi Schwartz, The Week US Published
-
'Wicked' and 'Gladiator II' ignite holiday box office
Speed Read The combination of the two movies revitalized a struggling box office
By Peter Weber, The Week US Published
-
Jussie Smollet conviction overturned on appeal
Speed Read The Illinois Supreme Court overturned the actor's conviction on charges of staging a racist and homophobic attack against himself in 2019
By Peter Weber, The Week US Published
-
Quincy Jones, music icon, is dead at 91
Speed Read The legendary producer is perhaps best known as the architect behind Michael Jackson's 'Thriller'
By Peter Weber, The Week US Published
-
OJ Simpson, star athlete tried for murder, dead at 76
Speed Read The former football hero and murder suspect lost his battle with cancer
By Rafi Schwartz, The Week US Published
-
Momofuku's 'Chili Crunch' trademark uproar
Speed Read The company's attempt to own the sole rights has prompted backlash
By Rafi Schwartz, The Week US Published